Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
USA116th CongressHRES-1125| House
| Updated: 9/18/2020
Eliot L. Engel
Democratic Representative
New York
Cosponsors (22)
Gilbert Ray Cisneros (Democratic)Barbara Lee (Democratic)David J. Trone (Democratic)Sheila Jackson Lee (Democratic)Terri A. Sewell (Democratic)Steve Cohen (Democratic)Donald M. Payne (Democratic)Adriano Espaillat (Democratic)Joaquin Castro (Democratic)Elaine G. Luria (Democratic)Gregory W. Meeks (Democratic)Jahana Hayes (Democratic)David E. Price (Democratic)Jerrold Nadler (Democratic)Ami Bera (Democratic)Eleanor Holmes Norton (Democratic)James P. McGovern (Democratic)Michael F. Q. San Nicolas (Democratic)Eddie Bernice Johnson (Democratic)Albio Sires (Democratic)Nanette Diaz Barragán (Democratic)Judy Chu (Democratic)
Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Health
Cardiovascular and respiratory healthCommunity life and organizationEmergency medical services and trauma careHealth care coverage and accessHealth programs administration and fundingImmunology and vaccinationInfectious and parasitic diseasesMedical researchMedical tests and diagnostic methodsMinority healthResearch administration and funding
Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
USA116th CongressHRES-1125| House
| Updated: 9/18/2020
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Eliot L. Engel
Democratic Representative
New York
Cosponsors (22)
Gilbert Ray Cisneros (Democratic)Barbara Lee (Democratic)David J. Trone (Democratic)Sheila Jackson Lee (Democratic)Terri A. Sewell (Democratic)Steve Cohen (Democratic)Donald M. Payne (Democratic)Adriano Espaillat (Democratic)Joaquin Castro (Democratic)Elaine G. Luria (Democratic)Gregory W. Meeks (Democratic)Jahana Hayes (Democratic)David E. Price (Democratic)Jerrold Nadler (Democratic)Ami Bera (Democratic)Eleanor Holmes Norton (Democratic)James P. McGovern (Democratic)Michael F. Q. San Nicolas (Democratic)Eddie Bernice Johnson (Democratic)Albio Sires (Democratic)Nanette Diaz Barragán (Democratic)Judy Chu (Democratic)
Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Cardiovascular and respiratory healthCommunity life and organizationEmergency medical services and trauma careHealth care coverage and accessHealth programs administration and fundingImmunology and vaccinationInfectious and parasitic diseasesMedical researchMedical tests and diagnostic methodsMinority healthResearch administration and funding